Johnson & Johnson Price to Free Cash Flow Ratio 2010-2024 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-07-26 |
160.64 |
|
21.16 |
| 2024-03-31 |
156.90 |
$7.59 |
20.67 |
| 2023-12-31 |
154.29 |
$7.27 |
21.23 |
| 2023-09-30 |
152.11 |
$6.28 |
24.22 |
| 2023-06-30 |
160.50 |
$5.63 |
28.53 |
| 2023-03-31 |
149.17 |
$6.23 |
23.94 |
| 2022-12-31 |
168.82 |
$6.65 |
25.37 |
| 2022-09-30 |
155.12 |
$6.80 |
22.82 |
| 2022-06-30 |
167.43 |
$7.60 |
22.02 |
| 2022-03-31 |
166.12 |
$7.52 |
22.10 |
| 2021-12-31 |
159.31 |
$7.65 |
20.81 |
| 2021-09-30 |
149.41 |
$8.72 |
17.13 |
| 2021-06-30 |
151.50 |
$8.77 |
17.27 |
| 2021-03-31 |
150.21 |
$8.14 |
18.45 |
| 2020-12-31 |
142.95 |
$7.67 |
18.63 |
| 2020-09-30 |
134.28 |
$6.91 |
19.43 |
| 2020-06-30 |
126.00 |
$6.65 |
18.95 |
| 2020-03-31 |
116.68 |
$8.50 |
13.72 |
| 2019-12-31 |
128.95 |
$8.64 |
14.93 |
| 2019-09-30 |
113.59 |
$9.35 |
12.15 |
| 2019-06-30 |
122.28 |
$8.74 |
13.99 |
| 2019-03-31 |
121.89 |
$8.04 |
15.16 |
| 2018-12-31 |
111.79 |
$7.97 |
14.04 |
| 2018-09-30 |
118.93 |
$7.48 |
15.91 |
| 2018-06-30 |
103.75 |
$7.70 |
13.47 |
| 2018-03-31 |
108.77 |
$7.36 |
14.77 |
| 2017-12-31 |
117.84 |
$7.14 |
16.50 |
| 2017-09-30 |
108.99 |
$7.11 |
15.33 |
| 2017-06-30 |
110.20 |
$6.62 |
16.64 |
| 2017-03-31 |
103.07 |
$6.33 |
16.28 |
| 2016-12-31 |
94.72 |
$6.03 |
15.72 |
| 2016-09-30 |
96.46 |
$5.86 |
16.45 |
| 2016-06-30 |
98.39 |
$6.19 |
15.89 |
| 2016-03-31 |
87.14 |
$6.66 |
13.09 |
| 2015-12-31 |
82.14 |
$6.96 |
11.81 |
| 2015-09-30 |
74.10 |
$6.13 |
12.09 |
| 2015-06-30 |
76.76 |
$6.80 |
11.29 |
| 2015-03-31 |
78.66 |
$6.56 |
11.99 |
| 2014-12-31 |
81.20 |
$6.85 |
11.85 |
| 2014-09-30 |
82.23 |
$6.76 |
12.17 |
| 2014-06-30 |
80.17 |
$5.83 |
13.76 |
| 2014-03-31 |
74.75 |
$5.49 |
13.61 |
| 2013-12-31 |
69.20 |
$4.96 |
13.95 |
| 2013-09-30 |
65.05 |
$4.94 |
13.18 |
| 2013-06-30 |
63.95 |
$4.71 |
13.57 |
| 2013-03-31 |
60.27 |
$4.64 |
12.99 |
| 2012-12-31 |
51.41 |
$4.97 |
10.35 |
| 2012-09-30 |
50.10 |
$5.02 |
9.98 |
| 2012-06-30 |
48.67 |
$5.05 |
9.64 |
| 2012-03-31 |
47.07 |
$4.83 |
9.75 |
| 2011-12-31 |
46.39 |
$4.59 |
10.10 |
| 2011-09-30 |
44.63 |
$4.62 |
9.65 |
| 2011-06-30 |
46.21 |
$4.71 |
9.81 |
| 2011-03-31 |
40.80 |
$4.72 |
8.65 |
| 2010-12-31 |
42.21 |
$5.21 |
8.10 |
| 2010-09-30 |
41.92 |
$5.76 |
7.28 |
| 2010-06-30 |
39.59 |
$5.69 |
6.96 |
| 2010-03-31 |
43.31 |
$5.50 |
7.87 |
| 2009-12-31 |
42.46 |
$5.15 |
8.25 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$384.202B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
